AQP3 activators may exert therapeutic effects on defects in the hydration, lubrication, and proliferation of the skin, bladder, vagina, and respiratory system, whereas AQP7 activators may be applicable as useful adjuvants for obesity treatment. Here, AQP7 is linked to obesity due to melanocortin 4 receptor deficiency.